Novel Alzheimer's disease Therapy to Slow Cognitive Decline?

Video

At AAN 2017, Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics, spoke with MD Magazine about his team’s two phase 3 studies in Alzheimer’s disease that studied a “well-established” target called the receptor for advanced glycation endproducts (RAGE).


Related Videos
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Shauna Applin, ARNP, an expert on HIV
Shauna Applin, ARNP, an expert on HIV
Shauna Applin, ARNP, an expert on HIV
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
A panel of 4 experts on HIV
© 2024 MJH Life Sciences

All rights reserved.